Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

Big Brother UK star Aisleyne Horgan-Wallace said she “thought she was going to die” after taking fake Ozempic. Horgan-Wallace ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...